@biopharmdeals.bsky.social
Reposted
‘What is already an innovation gap could become an innovation chasm.’
Large pharma companies withdrawing from R&D for infectious disease therapeutics has a growing impact on non-profit medical research orgs like DNDi, writes our R&D director in @statnews.com.
www.statnews.com/2025/10/09/p...
Large pharma companies withdrawing from R&D for infectious disease therapeutics has a growing impact on non-profit medical research orgs like DNDi, writes our R&D director in @statnews.com.
www.statnews.com/2025/10/09/p...
Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people
The number of “innovation champions” in the pharma industry working on infectious diseases is dropping — and that’s troubling, writes R&D director for Drugs for Neglected Diseases initiative.
www.statnews.com
October 9, 2025 at 10:35 AM
‘What is already an innovation gap could become an innovation chasm.’
Large pharma companies withdrawing from R&D for infectious disease therapeutics has a growing impact on non-profit medical research orgs like DNDi, writes our R&D director in @statnews.com.
www.statnews.com/2025/10/09/p...
Large pharma companies withdrawing from R&D for infectious disease therapeutics has a growing impact on non-profit medical research orgs like DNDi, writes our R&D director in @statnews.com.
www.statnews.com/2025/10/09/p...